Randomised trial
-
Adding irinotecan brought more side effects without improving rectal cancer outcomes
At 36 months, disease-free survival was 68% with irinotecan plus capecitabine chemoradiotherapy and 67% with capecitabine chemoradiotherapy alone, hazard ratio 0.91 (95% CI 0.68–1.23). This phase 3 randomised…
-
Higher-dose vitamin D did not slow metastatic colorectal cancer
Among 455 people starting treatment for metastatic colorectal cancer, median progression-free survival was 11.8 months with high-dose vitamin D3 and 10.3 months with standard-dose vitamin D3, a difference…
-
Nutrition drinks were linked to fewer chemotherapy changes after surgery
In a 157-person randomised trial, chemotherapy modifications occurred in 17.5% of patients given oral nutritional supplements plus dietary advice, versus 35.1% given dietary advice alone. Five-year all-cause mortality…
-
Short radiotherapy and chemotherapy improved five-year survival in rectal cancer
At five years, overall survival was 78.1% with short-course radiotherapy followed by chemotherapy, compared with 69.7% with long-course chemoradiotherapy, HR 0.739 (95% CI 0.550 to 0.993). Disease-free survival…
-
Tislelizumab regimen reached 45.3% pathological complete response in rectal cancer
In this 118-patient randomised phase II trial, adding tislelizumab to short-course radiotherapy and CAPOX chemotherapy was associated with a higher pathological complete response rate than the same treatment…
-
Cetuximab-irinotecan produced 18.8 versus 10.4 months median survival
In a 68-patient exploratory randomised trial, rechallenge with cetuximab plus irinotecan produced longer median progression-free and overall survival than regorafenib. The result is promising but comes from one…
-
Radiation boost improved nine-year disease-free survival by 23 percentage points
In a 106-person randomised phase II trial in locally advanced rectal cancer, a higher-dose radiation boost during preoperative chemoradiotherapy was associated with better nine-year disease-free and overall survival.…
-
AI assistance detected adenomas in 33.8% versus 30.9% in Lynch surveillance
In this randomised trial across nine specialist centres, adding the CAD EYE artificial intelligence system to high-definition colonoscopy did not significantly increase adenoma detection in people with Lynch…
-
Intensified preoperative treatment improved 3-year disease-free survival by 8.8 points
In a 458-patient randomised trial of high-risk locally advanced rectal cancer, a chemotherapy-intensified total neoadjuvant therapy regimen produced higher 3-year disease-free survival than conventional chemoradiotherapy. It also caused…